Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Toxoplasmosis Treatment Drugs Market, by Indication (Chronic Toxoplasmosis Infection, and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral, and Oral), by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa), is estimated to be valued at US$ 2,859.4 million in 2020 and is expected to exhibit a CAGR of 4.9% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Launch of novel products by market players to augment the market growth

 Increase in the toxoplasmosis infection is expected to boost the toxoplasmosis treatment drugs market growth. According to World Health Organization (WHO) Estimates of the Global Burden of Foodborne Diseases 2015, estimated that nearly 1 million cases of toxoplasmosis occurs annually in the European region which is caused by contaminated food. WHO stated that persons with compromised immune systems are at a higher risk of developing a toxoplasmosis infection.

Rising cancer cases is expected to cause toxoplasmosis and, thereby, drive the demand for toxoplasmosis treatment drugs market. For instance, according to the American Cancer Society 2020, around 178,520 people in the U.S. are estimated to be diagnosed with leukemia, lymphoma, or myeloma in 2020. According to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for nearly 1 out of every 4 deaths. According to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the U.S., with around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024.

Global Toxoplasmosis Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 113,820,168 infected individuals worldwide as of 1st March 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another.

Browse 34 Market Data Tables and 22 Figures spread through 164 Pages and in-depth TOC on ‘Toxoplasmosis Treatment Drugs Market - by Indication (Chronic Toxoplasmosis Infection, and Acute Toxoplasmosis Infection), by Route of Administration (Parenteral, and Oral), by Drug Class (Pyrimethamine, Spiramycin, Leucovorin, Sulfadiazine, Folic Acid, and Others), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Global Forecast to 2027’

To know the latest trends and insights prevalent in the global toxoplasmosis treatment drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/toxoplasmosis-treatment-drugs-market-4166

Key players in the market are focused on strategies such as mergers and research collaborations in order to advance the toxoplasmosis research and develop new disease treatments. For instance, in October 2016, Turing Pharmaceuticals announced a sponsored research agreement with the Washington University in St. Louis (WUSL) to investigate novel treatments for toxoplasmosis.

Key Takeaways of the Global Toxoplasmosis Treatment Drugs Market:

  • The global toxoplasmosis treatment drugs market is expected to exhibit a CAGR of 4.9% during the forecast period owing to the rising number of toxoplasmosis cases, rising number of chronic diseases such as cancer, sexually transmitted diseases. According to the study published in the National Center for Biotechnology Information (NCBI), 2018, patients with solid organ tumors treated with chemotherapy had the highest prevalence rate of toxoplasmosis (28%) and also found higher infection rate in males (26%) than females (10%) in the Egyptian cancer population.
  • Among route of administration, the oral segment held a dominant position in the toxoplasmosis treatment drugs market in 2019, as majority of generics which are launched recently are in the form of tablets
  • Among distribution channel, hospital pharmacies segment held a dominant position in the toxoplasmosis treatment drugs market in 2019, as majority of the cancer cases, and toxoplamsosis infection are registered at hospitals. Moreover, chemotherapy are majorly executed in hospitals.
  • Key players operating in the global toxoplasmosis treatment drugs market are Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd., Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.